Sepsis Diagnostics by Microbiology Technology Market Size (2023 - 2030)

Global Sepsis Diagnostics by Microbiology Technology Market is estimated to be worth USD 297.6 Million in 2022 and is projected to reach a value of USD 542.73 Million by 2030, growing at a CAGR of 7.8% during the forecast period 2023-2030.

Sepsis (septicemia in British English), or blood infection, is a severe medical condition and can be caused by the body's response to an infection harming its tissue and organs. It is characterized by fever, elevated rates of breathing and heartbeat, and mental confusion. Certain infections such as pneumonia may also lead to cough, and kidney infections may be linked to painful urination. Infants, the elderly, and individuals affected by weakened immunity may not exhibit any unique infection symptoms, such as a fever, but instead present a normal body temperature. When severe, sepsis can cause impaired organ function or blood flow. Signs include decreased blood pressure, increased blood lactate, and low urine output, suggestive of impaired circulation. Septic shock is a condition characterized by low blood pressure due to sepsis that does not improve despite fluid replacement.

Sepsis is a critical, life-threatening health condition that can be challenging to diagnose owing to the absence of specific symptoms or signs. When doctors are suspicious of sepsis, they look for more than two infections or related indications, conducting a thorough physical examination, various laboratory tests, and closely monitoring the condition of the patient. Sepsis can be caused by myriad diseases like pneumonia, diverticulitis, and other infectious organisms, such as bacteria, viruses, or fungi. If the patient presents a combination of symptoms and infections that fall into a risk group, and their medical history indicates an impaired immune system, sepsis is suspected. Important fever, hypotension, and loss of consciousness details must be considered and noted, as well as the patient's alcohol use and any current medications. For a sepsis diagnosis, numerous tests are performed to determine the potential and intensity of the illness, such as a urine test, a blood test, and relevant tests for other medical issues. An in-depth physical examination is also carried out to detect abscesses, prostatitis, or other neutropenic or pelvic infections.

Global Sepsis Diagnostics by Microbiology Technology Market Drivers:

The rising incidence of sepsis is fueling the growth of global sepsis diagnostics in the microbiology technology market.

Sepsis is a perilous, life-threatening health condition that occurs when the body responds negatively to an infection. It can damage organs and tissues and lead to septic shock or death, if not treated quickly. Recent studies suggest that around 49 million people suffer from sepsis annually, causing 11 million deaths. Sepsis often arises from preventable infections in the community and can also result from infections acquired in healthcare settings, which are frequent adverse events affecting millions of patients worldwide every year. Therefore, this factor drives the demand for sepsis diagnostics by microbiology technology.

The increasing initiatives by national governments and non-governmental entities toward the treatment of sepsis are another factor contributing to the growth of global sepsis diagnostics in the microbiology technology market.

Various government and non-government organizations are working vigorously to raise awareness about sepsis. Screening, educational campaigns, improved diagnostics, and treatment protocols are being deployed to cut down the mortality associated with sepsis. Global Sepsis Alliance and WHO have partnered with organizations from across the world to proliferate knowledge about this disease. WHO has enforced the Global Maternal Sepsis Study and Campaign to evaluate and manage sepsis cases pertaining to maternal health. Therefore, this factor also drives the demand for sepsis diagnostics by microbiology technology.

Global Sepsis Diagnostics by Microbiology Technology Market Challenges:

The global sepsis diagnostics by microbiology technology market is encountering challenges, primarily in terms of the high cost associated with automated diagnostic devices and the lack of skilled healthcare professionals. Businesses are developing advanced automated diagnostic devices using microbiology technology to detect sepsis, but government hospitals and academic research laboratories in emerging nations cannot afford such expensive systems due to restricted budgets. Moreover, sepsis is a life-threatening medical emergency requiring urgent clinical attention. Despite the prompt diagnoses and treatments needed, the world is now facing an immense shortfall of knowledgeable healthcare professionals, which is an alarming issue. Only 50% of patients with severe sepsis who are transported by the EMS system have access to a paramedic. This shortage of trained paramedics affects all aspects of patient care including sepsis awareness, identifying patients with sepsis, and providing appropriate treatment. Thus, these challenges inhibit the growth of global sepsis diagnostics in the microbiology technology market.

Global Sepsis Diagnostics by Microbiology Technology Market Opportunities:

The development of rapid sepsis diagnostic techniques presents a lucrative opportunity in the global sepsis diagnostics by the microbiology technology market. Given the rising demand for sepsis diagnostics by microbiology technology owing to the rising incidence of sepsis and the increasing initiatives by national governments and non-governmental entities toward the treatment of sepsis, businesses specializing in sepsis diagnostics can stand to gain significantly from this opportunity by developing rapid sepsis diagnosis to minimize delays in antibiotic therapy for sepsis patients. This development will help companies to increase their customer base and boost their overall revenue.

COVID-19 Impact on the Global Sepsis Diagnostics by Microbiology Technology Market:

The outbreak of the COVID-19 pandemic substantially impacted the global sepsis diagnostics by microbiology technology market. The implementation of strict lockdowns, traveling restrictions, and social distancing measures across several nations hindered many companies' manufacturing capacities and caused a shortage of skilled workforce. The pandemic caused disruptions in supply chains and distribution of goods and services, which highly affected the production and distribution of diagnostic tests and equipment used in sepsis diagnostics. Moreover, the shifted focus of healthcare infrastructure resources and personnel to COVID-19 testing and treatment further worsened the demand for sepsis diagnostics by microbiology technology. These factors negatively impacted the growth of global sepsis diagnostics in the microbiology technology market. Despite these challenges, the global sepsis diagnostics by microbiology technology market is projected to recover and grow in the coming years.

Global Sepsis Diagnostics by Microbiology Technology Market Recent Developments:

• In August 2022, Becton, Dickinson, and Company (BD), a US-based multinational medical technology company, entered into a global commercial partnership with Accelerate Diagnostics, Inc., a US-based in vitro diagnostics company. As part of this partnership, BD will provide Accelerate's rapid testing solution for detecting antibiotic resistance and susceptibility. This solution can produce results within hours, compared to the one to two days required by some conventional laboratory methods.
• In February 2021, Thermo Fisher Scientific Inc., a US-based supplier of scientific instrumentation, reagents and consumables, and software services, completed the acquisition of Mesa Biotech, Inc., a US-based biotechnology company.

SEPSIS DIAGNOSTICS BY MICROBIOLOGY TECHNOLOGY  MARKET REPORT COVERAGE:

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation:

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation: By Product

• Assays & Reagents
• Blood Culture Media
• Instruments
• Software

In 2022, the assays and reagents segment held the highest market share. The growth can be attributed to the assays and reagents being essential components of sepsis diagnosis. Procalcitonin and C-reactive protein are two examples of specific blood biomarkers associated with sepsis that can be detected using assays and reagents. These biomarkers are released by the body in response to infection and can be utilized to aid in the diagnosis and monitoring of the severity of sepsis. Because they are simple to use, highly sensitive, and specific, assays and reagents have become integral parts of sepsis diagnosis and treatment. The presence of biomarkers related to sepsis in the blood can be quickly identified using these tests, enabling medical professionals to promptly begin the appropriate treatment.

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation: By Method

• Automated Diagnostics
• Conventional Diagnostics

In 2022, the automated diagnostics segment held the highest market share. The growth can be attributed to the advantages that automated diagnostics offer in contrast to conventional diagnostics, including better traceability, high efficiency, and elimination of repetitive diagnostic practices. The demand for timely sepsis treatment has seen a surge in recent times, leading various significant players in the market to explore strategic initiatives such as mergers and acquisitions, partnerships, and the broadening of existing product portfolios to gain a larger share of the market. These strategic moves are driving the growth of the market. 

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation: By Pathogen Type

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

In 2022, the bacterial sepsis segment held the highest market share. The growth can be attributed to bacterial sepsis having a greater rate of incidence than other types of pathogens, particularly in healthcare settings, where individuals are more prone to contract infections. With a heightened risk of contracting sepsis, triggered by a wide range of bacteria, such as Staphylococcus aureus, Escherichia coli, and Streptococcus pneumoniae, rapid and timely intervention is required for optimal patient care. 

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation: By End User

• Hospitals & Clinics
• Diagnostic Centers
• Others

In 2022, the hospitals and clinics segment held the highest market share. The growth can be attributed to the high patient footfall in these healthcare settings. They offer comprehensive healthcare facilities, with dedicated laboratory facilities and trained medical professionals for efficient sepsis diagnostics. Hospitals also have critical care units and emergency departments for the timely intervention and management of septic patients. Additionally, sepsis often requires hospitalization, and hospitals provide a suitable environment for continuous monitoring and intervention. Access to resources, including advanced diagnostic equipment and skilled personnel, further enables hospitals and clinics to perform a variety of sepsis diagnostics efficiently.

Global Sepsis Diagnostics by Microbiology Technology Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

The region of North America dominated the global sepsis diagnostics by microbiology technology market in the year 2022. The presence of well-established healthcare infrastructure in nations, such as the United States and Canada, the high adoption rate of sepsis diagnostic devices in laboratory and medical clinics, favorable healthcare reimbursement policies, and the CDC's effort to raise awareness and prevention of sepsis through the "Get Ahead of Sepsis" campaign are some of the factors propelling the region's growth. Additionally, North America is home to several significant market players, including Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Luminex Corporation, T2 Biosystems, Inc., and Danaher Corporation.

The region of Asia-Pacific is anticipated to expand at the quickest rate over the forecast period owing to the rising incidence of sepsis condition, the increasing government's focus on the development of healthcare infrastructure in nations, such as China, India, and Japan, and the growing awareness about sepsis diagnosis and treatment.

Global Sepsis Diagnostics by Microbiology Technology Market Key Players:

1. bioMérieux SA (France)
2. Becton, Dickinson, and Company (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. Bruker Corporation (United States)
5. Luminex Corporation (United States)
6. Cepheid (United States)
7. T2 Biosystems, Inc. (United States)
8. Siemens Healthineers AG (Germany)
9. Danaher Corporation (United States)
10. Immunexpress Inc. (United States)